Phillip Halbert

Phillip Halbert has a diverse and extensive work experience spanning over several decades. Phillip began their career at Roche as an Oncology and Hospital Sales Specialist, where they successfully launched biologic cancer therapy Roferon-A and re-launched injectable antibiotic Rochephin. Phillip then joined Baxter International Inc. as a Critical Care Sales Representative, where they sold critical care medical equipment, inhaled anesthetic gases, and injectable products. Halbert achieved significant success in launching the inhaled anesthetic Suprane and relaunching the injectable beta-blocker Brevibloc.

Halbert then worked at Purdue Pharma L.P. as an Oncology and Institutional Representative, promoting pain and symptom management products to the oncology community, as well as regional anesthetic Chirocaine. After that, they joined Schering Pharmaceuticals as a Cardiovascular Hospital Specialist, selling acute care injectable cardiac medication Integrilin to cardiologists and emergency medicine physicians.

In 2008, Halbert joined Sanofi as a Diabetes Sales Specialist, where they played a crucial role in the successful launch of Soliqua, a combination of a basal insulin and a GLP-product, and the sale of Toujeo, a next-generation basal insulin. Additionally, they sold anticoagulant Lovenox and anti-platelet agent Plavix to various medical specialties, including pulmonologists/critical care, hospitalists, and surgical specialties.

Halbert's most recent work experience is at La Jolla Pharmaceutical Company, where they served as a Critical Care Specialist. Their responsibilities included the successful launch of a new vasopressor called Giapreza for the treatment of life-threatening hypotension in critically ill patients. Phillip achieved P&T approval for Giapreza in six hospitals within nine months and collaborated extensively with healthcare professionals across multiple specialties.

Overall, Halbert's work experience showcases their expertise and success in sales and launching new products, particularly in the fields of critical care, oncology, and diabetes.

Phillip Halbert has a Master of Business Administration (MBA) degree in Business Administration and Management, General from Mississippi State University. Phillip also obtained a Bachelor of Science (BS) degree in Microbiology, General from the same university. In addition to their degrees, Phillip has certifications in Bloodborne Pathogens in the Surgical Environment from HealthStream and Operating Room Protocol from AORN.